RS Oncology is a private biotech company based in Cambridge, MA USA. As a team of seasoned executives, scientists, and drug developers, we are building global partnerships to innovate new therapies. Our mission is to improve the lives and outcomes of patients with debilitating diseases and unmet medical needs.
RSO-021, our initial program, represents a novel class of oncology compounds that irreversibly bind and inhibit a key enzyme (PRX3) within the mitochondria of malignant cells. Currently in Phase 1/2 clinical development. ClinicalTrials.gov Identifier: NCT05278975.